Becton Dickinson

BioGx now offers 11 CE-marked infectious disease tests that run on Becton Dickinson's BD Max platform.

The firm has made two separate senior notes offerings in euros and British pounds, and it plans to use the proceeds to redeem other outstanding notes.

The firm raised its full fiscal year 2018 revenue and adjusted earnings per share guidance.

The company unveiled forthcoming products for high-throughput molecular testing, diagnostic lab informatics, and microbiology automation.

One outcome of a recent FDA workshop about the potential for using self-collection for Pap testing was that it might be better to do self-collection in combination with molecular testing.

The agency cleared two Roche tests that run on its Cobas systems. One does Chlamydia trachomatis and Neisseria gonorrhoeae testing and the other does hematology testing.

BD and the FDA said that a chemical called thiuram found in certain BD blood collection tubes may render results from Magellan's LeadCare blood lead tests inaccurate.

Pages